207 related articles for article (PubMed ID: 23325837)
21. Clinical and biological implications of mutational spectrum in acute myeloid leukemia of FAB subtypes M4 and M5.
Cheng Z; Hu K; Tian L; Dai Y; Pang Y; Cui W; Zhao H; Qin T; Han Y; Hu N; Chen L; Wang C; Zhang Y; Wu D; Ke X; Shi J; Fu L
Cancer Gene Ther; 2018 May; 25(3-4):77-83. PubMed ID: 29491461
[TBL] [Abstract][Full Text] [Related]
22. NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.
Rubio P; Campos B; Digiorge JA; Gallego MS; Medina A; Rossi JG; Felice MS; Alonso CN
Int J Hematol; 2016 Nov; 104(5):582-590. PubMed ID: 27436336
[TBL] [Abstract][Full Text] [Related]
23. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia.
Suzuki T; Kiyoi H; Ozeki K; Tomita A; Yamaji S; Suzuki R; Kodera Y; Miyawaki S; Asou N; Kuriyama K; Yagasaki F; Shimazaki C; Akiyama H; Nishimura M; Motoji T; Shinagawa K; Takeshita A; Ueda R; Kinoshita T; Emi N; Naoe T
Blood; 2005 Oct; 106(8):2854-61. PubMed ID: 15994285
[TBL] [Abstract][Full Text] [Related]
24. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study.
Walter RB; Kantarjian HM; Huang X; Pierce SA; Sun Z; Gundacker HM; Ravandi F; Faderl SH; Tallman MS; Appelbaum FR; Estey EH
J Clin Oncol; 2010 Apr; 28(10):1766-71. PubMed ID: 20159819
[TBL] [Abstract][Full Text] [Related]
25. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
[TBL] [Abstract][Full Text] [Related]
26. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities.
Khalidi HS; Medeiros LJ; Chang KL; Brynes RK; Slovak ML; Arber DA
Am J Clin Pathol; 1998 Feb; 109(2):211-20. PubMed ID: 9583894
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
[TBL] [Abstract][Full Text] [Related]
28. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
Haferlach T; Schoch C; Löffler H; Gassmann W; Kern W; Schnittger S; Fonatsch C; Ludwig WD; Wuchter C; Schlegelberger B; Staib P; Reichle A; Kubica U; Eimermacher H; Balleisen L; Grüneisen A; Haase D; Aul C; Karow J; Lengfelder E; Wörmann B; Heinecke A; Sauerland MC; Büchner T; Hiddemann W
J Clin Oncol; 2003 Jan; 21(2):256-65. PubMed ID: 12525517
[TBL] [Abstract][Full Text] [Related]
29. NPM1 gene mutation in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Sofan MA; Elmasry S; Salem DA; Bazid MM
Clin Lab; 2014; 60(11):1813-22. PubMed ID: 25648021
[TBL] [Abstract][Full Text] [Related]
30. BCL3 Expression Is a Potential Prognostic and Predictive Biomarker in Acute Myeloid Leukemia of FAB Subtype M2.
Niu Y; Yang X; Chen Y; Zhang L; Jin X; Tang Y; Li L; Yu L; Guo Y; Wang H
Pathol Oncol Res; 2019 Apr; 25(2):541-548. PubMed ID: 30357752
[TBL] [Abstract][Full Text] [Related]
31. Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome.
Mason EF; Hasserjian RP; Aggarwal N; Seegmiller AC; Pozdnyakova O
Blood Adv; 2019 Nov; 3(21):3322-3332. PubMed ID: 31698462
[TBL] [Abstract][Full Text] [Related]
32. [Immunophenotypic and clinical characteristic analysis of NPM1 mutated acute myeloid leukemia with a normal karyotype].
Liu YR; Lai YY; Chang Y; Ruan GR; Qin YZ; Wang YZ; Zhu HH; Shi HX; Jiang B; Jiang H; Jiang Q; Hao L; Li JL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1385-9. PubMed ID: 24370016
[TBL] [Abstract][Full Text] [Related]
33. [Clinical importance of morphological multilineage dysplasia in acute myeloid leukemia with myelodysplasia related changes].
Park SH; Chi HS; Park SJ; Jang S; Park CJ
Korean J Lab Med; 2010 Jun; 30(3):231-8. PubMed ID: 20603581
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.
Taskesen E; Bullinger L; Corbacioglu A; Sanders MA; Erpelinck CA; Wouters BJ; van der Poel-van de Luytgaarde SC; Damm F; Krauter J; Ganser A; Schlenk RF; Löwenberg B; Delwel R; Döhner H; Valk PJ; Döhner K
Blood; 2011 Feb; 117(8):2469-75. PubMed ID: 21177436
[TBL] [Abstract][Full Text] [Related]
35. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients.
Xu XQ; Wang JM; Gao L; Qiu HY; Chen L; Jia L; Hu XX; Yang JM; Ni X; Chen J; Lü SQ; Zhang WP; Song XM
Am J Hematol; 2014 Sep; 89(9):874-81. PubMed ID: 24861848
[TBL] [Abstract][Full Text] [Related]
36. Trisomy 11 as an isolated abnormality in acute myeloid leukemia is associated with unfavorable prognosis but not with an NPM1 or KIT mutation.
Alseraye FM; Zuo Z; Bueso-Ramos C; Wang S; Medeiros LJ; Lu G
Int J Clin Exp Pathol; 2011 Apr; 4(4):371-7. PubMed ID: 21577323
[TBL] [Abstract][Full Text] [Related]
37. Reclassification of Acute Myeloid Leukemia According to the 2016 WHO Classification.
Jung J; Cho BS; Kim HJ; Han E; Jang W; Han K; Lee JW; Chung NG; Cho B; Kim M; Kim Y
Ann Lab Med; 2019 May; 39(3):311-316. PubMed ID: 30623623
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
Marcucci G; Maharry K; Radmacher MD; Mrózek K; Vukosavljevic T; Paschka P; Whitman SP; Langer C; Baldus CD; Liu CG; Ruppert AS; Powell BL; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2008 Nov; 26(31):5078-87. PubMed ID: 18809607
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
40. Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity.
Bacher U; Schnittger S; Macijewski K; Grossmann V; Kohlmann A; Alpermann T; Kowarsch A; Nadarajah N; Kern W; Haferlach C; Haferlach T
Blood; 2012 May; 119(20):4719-22. PubMed ID: 22442349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
